Literature DB >> 11676864

High expression of thymidylate synthase leads to resistance to 5-fluorouracil in biliary tract carcinoma in vitro.

K Habara1, T Ajiki, T Kamigaki, T Nakamura, Y Kuroda.   

Abstract

To evaluate the effect of chemotherapy of 5-fluorouracil (5-FU) in human biliary tract carcinoma, we studied 5-FU sensitivity, thymidylate synthase (TS) content, and dihydropyrimidine dehydrogenase (DPD) activity in 4 human biliary tract carcinoma cell lines compared to 12 various digestive carcinoma cell lines of human organs in vitro. 5-FU sensitivity in the cell lines was analyzed by MTT assay. TS content was analyzed by the [6-(3)H]FdUMP binding assay method, and DPD activity was analyzed by thin-layer chromatography (TLC). 5-FU IC(50) values of biliary tract carcinoma cell lines were significantly higher than those of the carcinoma cell lines of the other digestive organs: 97, 45, 119, and 194 times the concentration of the other digestive, pancreas, colon, and gastric carcinoma cell lines, respectively. TS content of biliary tract carcinoma cell lines was also significantly greater than that of the carcinoma cell lines of the other organs. No difference in DPD activity, however, was recognized between the carcinoma cell lines of each organ. TS content in the cell lines significantly correlated with 5-FU sensitivity, but DPD activity did not. Therefore, in the present study, TS expression was concluded to influence the high resistance to 5-FU of biliary tract carcinoma in comparison with the carcinomas of the other digestive organs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676864      PMCID: PMC5926613          DOI: 10.1111/j.1349-7006.2001.tb01068.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  29 in total

1.  Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.

Authors:  M Kornmann; K H Link; H J Lenz; J Pillasch; R Metzger; U Butzer; G H Leder; M Weindel; F Safi; K D Danenberg; H G Beger; P V Danenberg
Journal:  Cancer Lett       Date:  1997-09-16       Impact factor: 8.679

2.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

Review 3.  Metabolism and mechanism of action of 5-fluorouracil.

Authors:  W B Parker; Y C Cheng
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

4.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines.

Authors:  A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde
Journal:  J Hepatol       Date:  1985       Impact factor: 25.083

Review 5.  Thymidylate synthase and drug resistance.

Authors:  G J Peters; C L van der Wilt; B van Triest; G Codacci-Pisanelli; P G Johnston; C J van Groeningen; H M Pinedo
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

6.  Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.

Authors:  H J Lenz; C G Leichman; K D Danenberg; P V Danenberg; S Groshen; H Cohen; L Laine; P Crookes; H Silberman; J Baranda; Y Garcia; J Li; L Leichman
Journal:  J Clin Oncol       Date:  1996-01       Impact factor: 44.544

7.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil.

Authors:  A Beck; M C Etienne; S Chéradame; J L Fischel; P Formento; N Renée; G Milano
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

8.  Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.

Authors:  H A Pitt; A Nakeeb; R A Abrams; J Coleman; S Piantadosi; C J Yeo; K D Lillemore; J L Cameron
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

Review 9.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

10.  Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil.

Authors:  Y Ishikawa; T Kubota; Y Otani; M Watanabe; T Teramoto; K Kumai; T Takechi; H Okabe; M Fukushima; M Kitajima
Journal:  Jpn J Cancer Res       Date:  2000-01
View more
  7 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.

Authors:  Nisana Tepsiri; Liengchai Chaturat; Banchob Sripa; Wises Namwat; Sopit Wongkham; Vajarabhongsa Bhudhisawasdi; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

Review 3.  Resistance mechanisms of gastrointestinal cancers: why does conventional chemotherapy fail?

Authors:  F Gieseler; P Rudolph; G Kloeppel; U R Foelsch
Journal:  Int J Colorectal Dis       Date:  2003-05-28       Impact factor: 2.571

4.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

5.  Histone deacetylase inhibitors sensitize 5-fluorouracil-resistant MDA-MB-468 breast cancer cells to 5-fluorouracil.

Authors:  Tetsuya Minegaki; Ai Suzuki; Misato Mori; Shiori Tsuji; Satoshi Yamamoto; Airi Watanabe; Tomoyo Tsuzuki; Takaki Tsunoda; Asuka Yamamoto; Masayuki Tsujimoto; Kohshi Nishiguchi
Journal:  Oncol Lett       Date:  2018-09-04       Impact factor: 2.967

6.  Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2+ Breast Cancer Cells to 5-Fluorouracil.

Authors:  Jianing Yi; Shuai Chen; Pingyong Yi; Jinlin Luo; Meng Fang; Yang Du; Lianhong Zou; Peizhi Fan
Journal:  Oncol Res       Date:  2020-07-29       Impact factor: 5.574

Review 7.  Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance.

Authors:  Jose J G Marin; Paula Sanchon-Sanchez; Candela Cives-Losada; Sofía Del Carmen; Jesús M González-Santiago; Maria J Monte; Rocio I R Macias
Journal:  Cancers (Basel)       Date:  2021-05-13       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.